17-Dec-2025
PRNewswire (Fri, 12-Dec 4:38 PM ET)
Announcement relating to despatch of Rule 15 proposal
Globe Newswire (Fri, 5-Dec 4:01 PM ET)
Alkermes to Participate in Two Upcoming Investor Conferences
Business Wire (Tue, 25-Nov 4:00 PM ET)
Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc
PRNewswire (Wed, 19-Nov 6:00 AM ET)
Avadel Board of Directors Declares Lundbeck Proposal a "Company Superior Proposal"
Globe Newswire (Mon, 17-Nov 5:45 AM ET)
Alkermes Response to Avadel Announcement
PRNewswire (Fri, 14-Nov 7:45 AM ET)
Avadel Receives Unsolicited Proposal from Lundbeck
Globe Newswire (Fri, 14-Nov 5:45 AM ET)
Market Chameleon (Wed, 12-Nov 2:58 AM ET)
PRNewswire (Wed, 12-Nov 7:30 AM ET)
ALKS Takes the Initiative: Alkermes Revealed as Offeror in Avadel Takeover Position Disclosure
Market Chameleon (Wed, 5-Nov 5:40 AM ET)
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Alkermes PLC - trades on the NASDAQ stock market under the symbol ALKS.
As of December 17, 2025, ALKS stock price declined to $28.04 with 1,669,216 million shares trading.
ALKS has a beta of 0.65, meaning it tends to be less sensitive to market movements. ALKS has a correlation of 0.08 to the broad based SPY ETF.
ALKS has a market cap of $4.63 billion. This is considered a Mid Cap stock.
Last quarter Alkermes PLC - reported $394 million in Revenue and $.49 earnings per share. This beat revenue expectation by $38 million and exceeded earnings estimates by $.12.
In the last 3 years, ALKS traded as high as $36.45 and as low as $22.01.
The top ETF exchange traded funds that ALKS belongs to (by Net Assets): IJR, VTI, IWM, VB, AVUV.
ALKS has underperformed the market in the last year with a price return of -8.6% while the SPY ETF gained +11.8%. However, in the short term, ALKS had mixed performance relative to the market. It has outperformed in the last 3 months, returning +2.4% vs +2.0% return in SPY. But in the last 2 weeks, ALKS shares have been beat by the market, returning -3.2% compared to an SPY return of -1.5%.
ALKS support price is $27.49 and resistance is $28.63 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALKS shares will trade within this expected range on the day.
